Nalaganje...
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
BACKGROUND: The identification of high-risk stage II colon cancers is key to the selection of patients who require adjuvant treatment after surgery. Microarray-based multigene-expression signatures derived from stem cells and progenitor cells hold promise, but they are difficult to use in clinical p...
Shranjeno v:
| izdano v: | N Engl J Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4784450/ https://ncbi.nlm.nih.gov/pubmed/26789870 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1506597 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|